Vector-Borne Diseases

Chapter 19


Vector-Borne Diseases



Learning Objectives


At the conclusion of this chapter, the reader should be able to:


• Describe the etiology, epidemiology, and signs and symptoms of Lyme disease.


• Analyze the immunologic manifestations and diagnostic evaluation of Lyme disease.


• Explain the principle, interpretation, and limitations of an antibody detection assay.


• Describe prevention strategies of Lyme disease.


• Summarize the etiology, epidemiology, and signs and symptoms of ehrlichiosis.


• Analyze the immunologic manifestations and diagnostic evaluation of ehrlichiosis.


• Explain the prevention of ehrlichiosis.


• Summarize the etiology, epidemiology, and signs and symptoms of Rocky Mountain spotted fever.


• Analyze the immunologic manifestations and diagnostic evaluation of Rocky Mountain spotted fever.


• Explain the prevention of Rocky Mountain spotted fever.


• Summarize the etiology, epidemiology, and signs and symptoms of babesiosis.


• Analyze the immunologic manifestations and diagnostic evaluation of babesiosis.


• Explain the prevention of babesiosis.


• Briefly discuss the etiology and laboratory diagnosis of West Nile virus infection.


• Analyze case studies related to the immune response in Lyme disease, Ehrlichiosis, and Babesiosis.


• Correctly answer case study related multiple choice questions.


• Be prepared to participate in a discussion of critical thinking questions.


• Describe the principle, limitations, and clinical applications of the rapid Borrelia burgdorferi antibody detection assay.


• Correctly answer end of chapter review questions.



Globalization has made the world a more connected place. Bacterial and viral diseases transmitted by mosquitoes, ticks, and fleas continue to be an ever-present threat worldwide (Table 19-1). Some of these diseases have been present in the United States for a long time but others have emerged recently. These include some of the world’s most destructive diseases, many of which are increasing threats to human health as the environment changes and globalization increases.



Table 19-1


Examples of Vector-Borne Diseases









































































































Vector Disease Pathogen Distribution
Mosquitoes      
Aedes triseriatus California encephalitis Virus United States: Upper Midwest, Appalachian region
Aedes aegypti Dengue fever
West Nile encephalitis
West Nile fever
Virus
Virus
Worldwide: tropical regions
United States; spreading nationwide
Africa, Asia
Culiseta melanura Eastern equine encephalitis Virus Eastern United States
Central and South America, Caribbean
Culex spp. St. Louis encephalitis
Western equine encephalitis
Virus
Virus
Eastern United States
Central and South America
Western United States
Central and South America
Ticks      
Deer tick, Ixodes spp. Anaplasmosis (formerly human granulocytic ehrlichiosis) Bacteria Worldwide; Europe
United States—Northeast, Upper Midwest, northern California
I. scapularis Babesiosis Protozoan parasite United States—primarily northeastern states, rarely Pacific states
Lone star tick, Amblyomma americanum Human monocytic ehrlichiosis Bacteria United States—Southeast, south central states
Dog tick, Rhipicephalus sanguineus Mediterranean spotted fever Bacteria Europe, Africa, Central Asia
Tickborne, airborne vector Q fever Rickettsiae Worldwide
Dog tick, wood tick, Dermacentor spp. Rocky Mountain spotted fever
Tick-associated rash, illness
Bacteria
Bacteria
North and South America
Southern
Ticks, various Tickborne relapsing fever Bacteria Western United States (endemic); Southern British Columbia; plateau regions of Mexico; Central and South America; Mediterranean, Central Asia, and much of Africa
Lice, Fleas, Mites      
Human body louse; squirrel flea and louse Epidemic typhus Rickettsiae United States, eastern
Rat flea, Xenopsylla cheopis Murine typhus Bacteria Worldwide, where rats are abundant
Cat or dog fleas Murine typhus–like febrile disease Rickettsiae Worldwide
Mites (chiggers) Scrub typhus Rickettsiae South Asia to Australia, East Asia in recently disturbed habitat (e.g., forest clearings or other persisting mite foci infested with rats and other rodents)
Human body louse Louse-borne relapsing fever
Trench fever
Bacteria
Rickettsiae
Africa
Industrialized countries


image


Most recent cases and outbreaks have occurred in rustic cabins at higher elevations (≥8000 ft) in coniferous forests in the western United States.


The discovery and surveillance of many of these vector-borne diseases (e.g., Lyme disease) can be accomplished by serologic testing. Travelers and military personnel may be at risk for exposure to vector-borne disease if they engage in activities that bring them into contact with habitats that support the vectors or the animal reservoir species associated with these diseases.


Some of the newly emerging infectious diseases in the United States include the following:



A few prominent examples of the more commonly occurring vector-borne diseases detectable by serologic methods are presented in this chapter.



Lyme Disease


Etiology


Lyme disease (Lyme borreliosis) is caused by a spirochete bacterium. It is a cutaneous systemic infection generally transmitted by a hard-bodied tick (Fig. 19-1) and caused by Borrelia burgdorferi (Fig. 19-2). The causative agent of Lyme borreliosis currently consists of three pathogenic species—B. burgdorferi, Borrelia afzelii, and Borrelia garinii. Only B. burgdorferi strains have been found in the United States. In contrast, most of the illness in Europe is caused by B. afzelii, which is associated with the chronic skin condition acrodermatitis chronica atrophicans (ACA), and B. garinii, which is associated with neurologic symptoms. Only these two species have been found in Asia. The complete genome of B. burgdorferi (strain B31) has now been sequenced.




The spirochete is transmitted by certain ixodid ticks that are part of the Ixodes ricinus complex. These include Ixodes scapularis (formerly classified as Ixodes dammini) in the northeastern and Midwestern United States, Ixodes pacificus in the western United States, Ixodes ricinus in Europe, and Ixodes persulcatus in Asia. The vector has not been identified in Australia. Ixodid ticks are also indigenous to Africa and South America. The lone star tick, Amblyomma americanum, does not transmit Lyme disease.


In the United States, the preferred host for larval and nymphal stages of I. scapularis is the white-footed mouse, Peromyscus leucopus. White-tailed deer, which are not involved in the life cycle of the spirochete, are the preferred host for the I. scapularis adult stage and they seem to be critical to tick survival. Ixodid ticks have also been found on at least 30 types of wild animals and 49 species of birds. Illness is not known to develop in wild animals, but clinical Lyme disease does occur in domestic animals, including dogs, horses, and cattle.


Spirochetes are transmitted from the gut of the tick to human skin at the site of a bite and then migrate outwardly into the skin. This migration causes the unique expanding skin lesion, erythema migrans (EM). Subsequent dissemination of spirochetes to secondary sites may cause major organ system involvement in humans. In dogs, the most common symptom is arthritis.



Epidemiology


Currently, Lyme disease is a global illness. Cases have been reported on all continents except Antarctica. Since its original description more than 25 years ago, Lyme disease has become the most commonly reported (95%) vector-borne illness in the United States. This infection has emerged as a major health hazard for human beings and domestic animals. In 2011, it was the sixth most common nationally notifiable disease. It is endemic in more than 15 states in the United States and in Europe and Asia.


In some patients, Lyme disease may be transitory and of little consequence, but in others it may become chronic and severely disabling. Accurate diagnosis is therefore essential, although better laboratory techniques are still needed.


Retrospectively, the first symptom of Lyme disease apparently was recognized as early as 1908 in Sweden. In the decades that followed, the rash produced by the disease erythema chronicum migrans (ECM) was noted elsewhere in Europe, as were other symptoms that seemed to follow ECM’s eruption. Secondary symptoms, such as impairment of the nervous system, were described in France, Germany, and again in Sweden.


In the United States the European rash was almost unknown until 1969, when a case of a physician bitten by a tick while hunting in Wisconsin was reported. Although a few ECM cases were seen in Americans who had traveled to Europe, there were no further native American cases until 1975, when physicians at the U.S. Navy base in Groton, Connecticut, reported seeing four patients with a rash similar to that of ECM. At the same time, an epidemiologist at the Connecticut State Department of Health and a rheumatologist at Yale University were notified of an unusual cluster of cases of arthritis occurring in children in Lyme, Connecticut.


It was not until 1982 that Burgdorfer and Barbour isolated a previously unrecognized spirochete, now called B. burgdorferi, from I. scapularis ticks, and Lyme disease became a recognized vector-borne, infectious disease. Two factors influence the chance that a bitten patient will contract the disease, the likelihood that local ixodid ticks carry the Lyme spirochete and the likelihood of infection after a bite by an infected tick. The probability of infection after an ixodid tick bite in an area of endemic disease is about 3%, but varies in different regions from less than 1% to as high as 5%. It has been suggested that human leukocyte antigen (HLA)–DR4 (HLA-DR4) and, secondarily, HLA-DR2, may increase the risk that Lyme arthritis will become chronic and fail to respond to antibiotics.


Lyme disease does not occur nationwide and is concentrated heavily in the northeast and upper midwest. The highest number of confirmed cases of Lyme disease to date was 29,959 in 2009 (Fig. 19-3). Persons of all ages and both genders are equally susceptible. In 2011, 96% of Lyme disease cases were reported from 13 states (Fig. 19-4):





Lyme disease is considered an emerging infectious disease because of the impact of changing environmental and socioeconomic factors, such as the transformation of farmland into suburban woodlots favorable for deer and deer ticks. Although pets may represent a spirochete reservoir, it is unlikely that humans can be infected directly by them. In areas of endemic Lyme disease, however, both adult and nymphal ticks, carried into the household by dogs and cats, may infect humans.



Signs and Symptoms


The basic features of Lyme disease are similar worldwide, but there are regional variations, primarily between the illness in America and that in Europe and Asia. In at least 60% to 80% of U.S. patients, Lyme disease begins with a slowly expanding skin lesion, EM, which occurs at the site of the tick bite. The skin lesion is frequently accompanied by flulike symptoms.


The Centers for Disease Control and Prevention (CDC) clinical case definition for Lyme disease includes the presence of EM or at least one objective, late manifesting sign of musculoskeletal, neurologic, or cardiovascular disease and a positive serologic test for antibodies to B. burgdorferi. Many misdiagnosed patients actually have chronic fatigue syndrome or fibromyalgia, both of which can cause similar symptoms, such as joint stiffness or pain, fatigue, and sleep disturbance.


Lyme borreliosis is a multisystem illness that primarily involves the skin, nervous system, heart, and joints (Table 19-2). Lyme disease usually begins during the summer months with EM and flulike symptoms and may be accompanied by right upper quadrant tenderness and a mild hepatitis (stage 1). This stage is followed weeks to months later by acute cardiac or neurologic disease in a minority of untreated individuals (stage 2) and then by arthritis and chronic neurologic disease (stage 3) in many untreated patients weeks to years after disease onset. There is considerable overlap of these stages, but Lyme disease is best characterized as an illness that evolves from early to late disease without reference to an arbitrary staging system. However, a patient may have one or all of the stages, and the infection may not become symptomatic until stage 2 or 3. Most affected patients have EM and 25% manifest arthritis; neurologic manifestations and cardiac involvement are uncommon.




Arthritis


Arthralgia and myalgia are common features of early Lyme disease, but frank arthritis during EM is unusual. Arthritis is a well-described complication of Lyme disease and characteristically occurs months to years after Borrelia infection. Therefore, cases of Lyme arthritis occur during every month of the year. Lyme arthritis and parvovirus B19 arthritis can occur in the absence of other symptoms, such as the characteristic rash. Some suspected cases of Lyme arthritis might be caused by parvovirus B19, particularly those occurring during the parvovirus B19 season.


Arthritis in patients with chronic Lyme disease may be associated with a long-standing infiltration of the joints by B. burgdorferi spirochetes, along with a local inflammatory response. It may not be triggered simply by the presence of circulating immunoglobulin G (IgG) antibodies against outer surface proteins.



Cutaneous Manifestations


Cutaneous manifestations can be demonstrated as early ECM (Fig. 19-5), secondary lesions (disseminated lesions and lymphocytoma), and late lesions (ACA). Except for the late lesions, cutaneous manifestations generally resolve spontaneously over weeks to months. The red papule at the site of the tick bite is most often located on the thigh, groin, or axilla. Facial EM is seen more frequently in children.



Several days to weeks after the onset of EM, almost 50% of untreated patients develop secondary skin lesions. A rare early manifestation of Lyme disease is Borrelia lymphocytoma, a violaceous, tumor-like swelling or nodule at the base of the earlobe or nipple caused by a dense lymphocytic infiltrate of the dermis. This lesion occurs at the site of a tick bite and in conjunction with other symptoms; it may be confused with lymphoma.


ACA is a late skin manifestation of Lyme disease more prevalent in Europe than in the United States. Lesions display bluish red discoloration, doughy swelling, and fibrotic nodules. Eventually, striking atrophy of the skin and subcutaneous tissues follows. Polyneuropathy coexists in 30% to 45% of patients.



Cardiac Manifestations


Lyme carditis occurs in approximately 8% of untreated patients within 1 to 2 months (range, >1 week to 7 months) after the onset of infection and may be the initial manifestation of Lyme disease. Cardiac features of Lyme disease usually result in a fluctuating degree of atrioventricular conduction defects (first-degree, second-degree, and complete block, as well as bundle branch and fascicular blocks) or tachyarrhythmias. Myopericarditis can occur, but symptomatic congestive heart failure is uncommon. Patients usually develop signs of lightheadedness, syncope, dyspnea, palpitations, and chest pain. Symptoms are more common in patients with more severe degrees of heart block. The carditis usually follows a self-limited and mild course, but temporary pacing may be needed in a small percentage of patients.



Neurologic Manifestations


Neurologic abnormalities occur in approximately 15% of untreated patients. These are usually observed 2 to 8 weeks after disease onset and may include aseptic meningitis, cranial nerve palsies, peripheral radiculoneuritis, and peripheral neuropathy. The predominant symptoms of Lyme meningitis are severe headache and mild neck stiffness, which may fluctuate for weeks after a post-EM latent period.


Months to years after the initial infection with B. burgdorferi, patients with Lyme disease may have chronic encephalopathy, polyneuropathy or, less often, leukoencephalitis. The appearance of mild encephalopathy has been seen 1 month to 14 years after the onset of disease. Encephalopathy is characterized by memory loss, mood changes, or sleep disturbances. In addition, increased cerebrospinal fluid (CSF) protein levels and evidence of intrathecal production of antibody to B. burgdorferi may occur. Chronic neurologic manifestations can also include polyneuropathy with radicular pain or distal paresthesias, fatigue, headache, hearing loss, and verbal memory impairment. These chronic neurologic abnormalities usually improve with antibiotic therapy.


Ocular manifestations may occur in Lyme disease and include cranial nerve palsies, optic neuritis, panophthalmitis with loss of vision, and choroiditis with retinal detachment.




Immunologic Manifestations


Cellular immune responses to B. burgdorferi antigens begin concurrent with early clinical illness. An increase in spontaneous suppressor cell activity and reduction in natural killer (NK) cell activity have been noted. Mononuclear cell, antigen-specific responses develop during spirochetal dissemination and humoral (antibody) immune responses soon follow.


Serodiagnostic tests are insensitive during the first several weeks of infection. In the United States, approximately 20% to 30% of Lyme patients have positive responses, usually of the IgM isotype, during this period, but by convalescence 2 to 4 weeks later, about 70% to 80% have seroreactivity even after antibiotic treatment. After about 1 month, most patients with an active infection have IgG antibody responses. After antibiotic treatment, antibody titers slowly fall, but IgG and even IgM responses may persist for many years after treatment. An IgM response cannot be interpreted as a manifestation of recent infection or reinfection unless the appropriate clinical characteristics are present. Antibodies formed include cryoglobulins, immune complexes, antibodies specific for B. burgdorferi, and anticardiolipin antibodies. Elevated titers of IgM are noted in early disease. Immunoblot analysis demonstrates that IgM antibodies form initially against the flagellar 41-kilodalton (kDa) polypeptide, but react later to additional cell wall antigens. An overlapping IgG response to these antigens develops in some individuals. These antigen-specific cellular and humoral responses are not known to eradicate infection in early disease or participate in disease pathogenesis.


Specific IgM or IgG antibodies against B. burgdorferi are usually not detectable in a patient’s serum unless symptoms have been present for at least 2 to 4 weeks. In cases of Lyme arthritis, tests for serum antinuclear antibodies (ANAs) and rheumatoid factor (RF) and Venereal Disease Research Laboratory (VDRL) test results are generally negative. However, anti–B. burgdorferi antibodies of the IgG type should be present in the serum of patients with Lyme arthritis.


Outer surface protein A antibodies develop late in the course of human Lyme infection and then only in a subset of patients. A temporal association may exist between the onset of chronic Lyme arthritis in four patients who were HLA-DR4–positive and the development of antibodies to the outer surface protein.


Persistent organisms and spirochetal antigen deposits elicit a vigorous immune reaction, as manifested by a tissue-rich plasma cell and lymphocytic exudate containing abundant T cells, predominantly of the helper subset, plus IgD-bearing B cells. B. burgdorferi antigens elicit a strong immune reaction that intensifies with chronicity of arthritis and stimulates macrophages to secrete interleukin-1 (IL-1). IL-1 is capable of stimulating synovial cells and fibroblasts to secrete collagenase and prostaglandin E2; levels of both are elevated in Lyme synovial fluid and can cause erosion of joint cartilage and bone.


Jun 12, 2016 | Posted by in IMMUNOLOGY | Comments Off on Vector-Borne Diseases

Full access? Get Clinical Tree

Get Clinical Tree app for offline access